

ABSTRACT

Provided are compounds having superior TAFIa inhibitory activity. Specifically, there are provided compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof:



(I)

wherein A is a benzene ring or a pyridine ring; X is the formula $-(CH_2)-$, the formula $-(CH_2)_2-$, an oxygen atom, a nitrogen atom or a single bond; Y is the formula $-(CH_2)_3-NH-R^3$, the formula $-(CH_2)_4-NH-R^3$ or a 2-aminopyridyl group; R^3 is a hydrogen atom, a C_{1-6} alkyl group, or the formula $-CO_2R^4$; R^4 is a C_{1-6} alkyl group, the formula $-CHR^5OC(O)R^6$, or a substituent having the structure represented by the following formula Ia;



(Ia)

R^5 is a C_{1-6} alkyl group; R^6 is a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, or a phenyl group; R^7 is a C_{1-6} alkyl group or a phenyl group; R^1 is a hydrogen atom, a halogen atom, a C_{1-4} alkyl group substituted by 1-3 halogen atoms, a C_{1-10} alkyl group, a C_{1-8} alkoxy group, a C_{3-8} cycloalkyl group, a C_{3-8} cycloalkoxy group, a C_{4-14} cycloalkylalkyl group, or a phenyl group; R^2 is CO_2R^8, or a tetrazolyl group; R^8 is a hydrogen

atom, a C_{1-10} alkyl group, or a substituent having the structure represented by the following formula Ib or Ic;



(Ib)



(Ic)

m and n are each an integer of zero or one.